{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:13:17Z","timestamp":1779297197687,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100215","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:19:04Z","timestamp":1773145144000},"page":"100215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4531-7859","authenticated-orcid":false,"given":"Martha L.","family":"Louzada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9686-4323","authenticated-orcid":false,"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-9437","authenticated-orcid":false,"given":"Victor H.","family":"Jimenez- Zepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4368","authenticated-orcid":false,"given":"Arleigh","family":"Mccurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5453","authenticated-orcid":false,"given":"Debra","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Stakiw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-8764","authenticated-orcid":false,"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayan","family":"Kaedbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3215","authenticated-orcid":false,"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2026.100215_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.bneo.2026.100215_bib2","series-title":"SEER Cancer Statistics Review, 1975-2007","year":"2010"},{"issue":"14","key":"10.1016\/j.bneo.2026.100215_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.bneo.2026.100215_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bneo.2026.100215_bib5","first-page":"3145","article-title":"Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor","volume":"130","author":"Spencer","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100215_bib6","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bneo.2026.100215_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2026.100215_bib8","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2018.36.15_suppl.8032","article-title":"Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR","volume":"36","author":"Orlowski","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.bneo.2026.100215_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100215_bib10","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2026.100215_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100215_bib12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2026.100215_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2026.100215_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bneo.2026.100215_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/10428194.2014.907890","article-title":"The role of P-glycoprotein in drug resistance in multiple myeloma","volume":"56","author":"Abraham","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"38","key":"10.1016\/j.bneo.2026.100215_bib16","doi-asserted-by":"crossref","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Franqui-Machin","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bneo.2026.100215_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100215_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.bneo.2026.100215_bib19","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100215_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100215_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","volume":"13","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bneo.2026.100215_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jha2.894","article-title":"Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"5","author":"Kaedbey","year":"2024","journal-title":"EJHaem"},{"issue":"12","key":"10.1016\/j.bneo.2026.100215_bib23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100215_bib24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.13678","article-title":"Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada","volume":"107","author":"Reece","year":"2021","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100215_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10214","key":"10.1016\/j.bneo.2026.100215_bib26","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bneo.2026.100215_bib27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/bjh.18703","article-title":"Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: a real-world multicentre UK retrospective analysis","volume":"201","author":"McMillan","year":"2023","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100215_bib28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100215_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100215_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.bneo.2026.100215_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100215_bib32","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1182\/blood-2024-210345","article-title":"High-risk multiple myeloma in benefit (IFM 2020-05) phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus Isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI)","volume":"144","author":"Corre","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bneo.2026.100215_bib33","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100215_bib34","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.clml.2023.11.008","article-title":"Predictors and impact of timing of disease progression following primary therapy in multiple myeloma","volume":"24","author":"Goldman-Mazur","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:26:20Z","timestamp":1779294380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000269"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100215","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100215"}}